Pharnext 주식 가격. ALPHA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

0.0002

매수가

0.0001

매도가

0.0002

거래량

0.00

0.00 일간 변동폭 0.00

0.0001 52주 범위 1.21

market_cap

17.505

전일 종가

0.0002

개장가

최근 거래 시간

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

0.00

발행 주식

87,525

배당수익률

주가수익률

-15.90

주당순이익(EPS)

-314.39

매출

174k

순이익

-27.52M

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

pharnext.com/

본부

Suresnes, Hauts-de-seine, Fra

설립됨

Pharnext is listed in the Pharmaceutical Preparations sector of the 유로넥스트 (Euronext) with ticker ALPHA. The last closing price for Pharnext was 0.00 €. Over the last year, Pharnext shares have traded in a share price range of 0.0001 € to 1.21 €.

Pharnext currently has 87,525 shares in issue. The market capitalisation of Pharnext is 17.51 € . Pharnext has a price to earnings ratio (PE ratio) of -15.90.

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday...

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time New Data from the...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with ...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traiteme...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traitement avec PXT3003 chez les patients atteints de la maladie de...

Europäische Arzneimittelagentur stimmt dem pädiatrischen Prüfkonzept für PXT3003 von Pharnext zu

Diese Zustimmung bereitet den Weg für die Stellung eines Marktzulassungsantrags in Europa Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), ein biopharmazeutisches Unternehmen und...

European Medicines Agency Agrees with Pharnext’s Pediatric Investigation Plan for PXT3003

This agreement paves the way for the submission of a marketing authorization application in Europe Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), a...

Pharnext will Topline-Ergebnisse der zulassungsrelevanten Phase-3-Studie zu PXT3003 zur Behandlung der Charcot-Marie-Tooth-Kr...

Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), ein biopharmazeutisches Unternehmen und Vorreiter eines neuen Ansatzes zur Entwicklung innovativer Medikamentenkombinationen, die auf Big...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0.0002	0.0002	0.0002	0	0	DE
4	0	0	0.0002	0.0002	0.0002	0	0	DE
12	0	0	0.0002	0.0002	0.0002	0	0	DE
26	-0.0318	-99.375	0.032	0.042	0.0001	3089983	0.0012115	DE
52	-0.0044	-95.652173913	0.0046	1.21	0.0001	26222057	0.00084405	DE
156	-0.0898	-99.7777777778	0.09	1.95	0.0001	61388886	0.00380228	DE
260	-4.2398	-99.9952830189	4.24	7	0.0001	37554276	0.00730074	DE

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ALCOXNicox SA	0.2895 € (32.49%)	1.34M
ALGTRGroupe Tera SA	2.40 € (28.34%)	410
ALSAFSAFE	0.086 € (23.92%)	80.01k
ALAGOEPango SA	0.1062 € (16.45%)	2.54M
MLCMIScemi	3.96 € (14.45%)	4
ALCYBCybergun	0.0001 € (-50.00%)	2.68M
ALTMENoxxon Pharma NV	0.0896 € (-42.34%)	4.69M
GNROGeNeuro SA	0.0428 € (-34.56%)	1.05k
ALEUPEuroplasma	0.047 € (-32.86%)	2.61M
ATOAtos SE	0.339 € (-31.52%)	14.65M
ALNEVNeovacs	0.0003 € (0.00%)	52.59M
BCPBanco Comercial Portugues SA	0.4469 € (0.27%)	34.35M
ATOAtos SE	0.339 € (-31.52%)	14.65M
ORAOrange.	9.414 € (-3.01%)	14.62M
ALHPIHopium SA	0.0089 € (3.49%)	11.09M